Torrent Pharma

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.

The insolvency process of debt-ridden Reliance Capital Ltd (RCL) on Tuesday hit a roadblock as the NCLT Mumbai has stayed the resolution process on the plea of Torrent Group. The stay order was issued by the National Company Law Tribunal (NCLT) as the Ahmedabad-based Torrent Group challenged the revised bid from Hinduja Group, sources said. Torrent Group, which emerged as the highest bidder with an Rs 8,640 crore offer, had moved the NCLT-Mumbai against Hinduja Group's late revised bid, which it had submitted after the completion of the e-auction process on December 21. A day after the e-auction, Hinduja Group, the promoter of IndusInd Bank, revised its offer from Rs 8,110 crore to Rs 9,000 crore. This is the first time that an e-auction of this scale is taking place for the resolution of an NBFC (non-banking financial company) under the Insolvency and Bankruptcy Code (IBC). The decision of e-auction was taken at the behest of LIC and EPFO, which together control 35 per cent of th

CoC decide whether Hinduja offer is legally valid or not as e-auction has ended

Stocks to Watch Today: Shares of Sula Vineyards likely to list on a tepid note on Thursday.

Torrent Pharmaceuticals on Wednesday said it has inked a pact with Boehringer Ingelheim India to co-market diabetes drug and its combinations in the country. The company has inked an agreement to jointly sell Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin). Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. It is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. "I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian pharmaceutical market," Torrent Pharmaceuticals Director Aman Mehta said in a statement. Boehringer Ingelheim India Managing Direct

After the anti-diabetic market, India's cardiac market in for a shake-up

According to GT Bharat's monthly Dealtracker, the biggest deal in October was Torrent Pharma's $250 million acquisition of Curatio Healthcare

What do expect from pharma stocks over the next few weeks? Here's what technical charts suggest.

Brazil revenues for the quarter came in at Rs 185 crore, up by 19 percent. US revenues for the quarter were Rs 292 crore, up by 3 percent. Germany revenue was down 12 percent to Rs 220 crore

Torrent Pharmaceuticals on Friday reported a marginal decline in its consolidated net profit at Rs 312 crore for the second quarter ended September 2022. The company had posted a consolidated net profit of Rs 316 crore in the year-ago period. Revenue from operations rose to Rs 2,291 crore in the July-September quarter as against Rs 2,137 crore in the year-ago period, Torrent Pharma said in a statement. The company said its domestic revenue stood at Rs 1,224 crore during the period under review. The drug firm also reported robust sales across various international markets like the US, and Brazil, it added. Shares of the company on Friday ended 0.99 per cent down at Rs 1,578 apiece on the BSE.

Stock to watch today: Nykaa's board meeting will be held on October, 3 to consider and approve the issuance of bonus shares

ICICI Securities is positive on Torrent's ability of faster integration and turnaround of acquired assets in the domestic space

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Reliance Capital is undergoing a bankruptcy process and the administrator had sought offers for the entire company and for its various business clusters

CLOSING BELL: It was a range-bound trade on the bourses on Friday as investors awaited US Fed chief Jerome Powell's address at the Jackson Hole Symposium later tonight

Stocks to watch today: Titan plans to add 20 to 30 Tanishq stores over two to three years in the Middle East and North America; Nelco inked pact with Intelsat to provide inflight connectivity services

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Ambuja Cements, Ceat, Eicher Motors, Pidilite Industries, Tata Chemicals, Torrent Power and Wockhardt are few of the prominent stocks holding on to the bullish outlook.

Last year, Aman had told Business Standard that they were still quite flexible to take up roles within the organisation